Abbott Laboratories $38.66

up +0.06


23/4/2014 09:43 AM  |  NYSE : ABT  
Industries : Health Services / Medical Appliances & Equipment
Get Trend Analysis Icon Get ABT Trend Analysis - it has underperformed the S&P 500 by 16%

Partner Headlines

  1. Market Wrap For April 21: S&P 500 Extends Winning Streak To Five Days, ...

    Benzinga
  2. Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories

    Benzinga
  3. Abbott Labs Q1 sales, EPS fall

    IBD
  4. Market Wrap For April 16: Markets Hold On To Gains An Positive Yellen Comments ...

    Benzinga
  5. Abbott Q1 Performance Slips, But EPS Tops Estimates

    IBD
  6. Stock Futures In Positive Mode; Yahoo Rockets On Alibaba Boost

    IBD
  7. UPDATE: Abbott Posts Upbeat Q1 Earnings

    Benzinga
  8. Earnings Scheduled For April 16, 2014

    Benzinga
  9. Stocks To Watch For April 16, 2014

    Benzinga
  10. Intuitive Surgical Made Sci-Fi Dreams A Reality

    IBD
  11. Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the ...

    Benzinga
  12. Absolute and Relative Valuation Models Indicate the Same: Abbot Is a Buy

    GuruFocus
  13. We Are Confident About Baxter's Plan to Create Two Separate Health Care ...

    GuruFocus
  14. Baxter Splitting In Effort To 'Unlock Trapped Value'

    IBD
  15. TripAdvisor: Yelp of Travel Looks Too Pricey

    YCharts
  16. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  17. Lountzis Asset Management Comments on Abbott Laboratories

    GuruFocus
  18. Abbott Capturing Incremental Market Share

    GuruFocus
  19. Abbvie's Humira Continues to be a Powerful Catalyst for Growth

    GuruFocus
  20. Morgan Stanley Sees 2015 Numbers Going Higher for Abbott Laboratories

    Benzinga
  21. AbbVie’s Testosterone: Impact of Health Concerns

    YCharts
  22. Morgan Stanley Maintains on Abbott Laboratories

    Benzinga
  23. Abbott EPS meets, sales miss

    IBD
  24. Abbott Labs Q4 Sales Miss Estimates; Earnings In Line

    IBD
  25. Earnings Scheduled For January 22, 2014

    Benzinga
  26. Stocks To Watch For January 22, 2014

    Benzinga
  27. UPDATE: Morgan Stanley Upgrades Abbott Laboratories

    Benzinga
  28. Diamond Hill Capital Comments on Abbott Laboratories

    GuruFocus
  29. Morgan Stanley Upgrades Abbott Based on Reacceleration

    Benzinga
  30. Dividend Aristocrat Johnson & Johnson Offers Growth

    IBD
  31. Drugmakers End Louisiana Suit Over Inflated Prices

    YCharts
  32. Johnson & Johnson (JNJ) Dividend Stock Analysis

    GuruFocus
  33. AbbVie Hepatitis C Treatment Shines In Latest Trials

    IBD
  34. Investing in Generation Y and the Next Great Baby Boom

    GuruFocus
  35. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  36. Johnson & Jonhson Unit Could Fetch Over $4 Billion in Sale

    Benzinga
  37. AbbVie’s AndroGel Testosterone Hit By Heart Study

    YCharts
  38. Where J&J $2.2B Settlement Fits Among Biggest

    YCharts
  39. AbbVie beats on Humira sales

    IBD
  40. AbbVie Earnings Beat Estimates; Street Eyes HCV Drugs

    IBD
  41. Generic Drug Industry: Top Five Players

    YCharts
  42. Starbucks Comes Under Official Chinese Criticism For Prices

    Benzinga
  43. 13 Companies Creating Real Wealth with Higher Cash Dividends

    GuruFocus
  44. 4 Big Players With Recent Dividend Growth To Consider

    GuruFocus
  45. Barron's Recap: Return Of The Bulls

    Benzinga
  46. Detecting Malaria Using a Cell's Electric Vibe

    FoxBusiness
  47. Market Primer: Thursday, October 17: US Debt Deal Kicks The Can

    Benzinga
  48. Abbott Q3 profit beats views

    IBD
  49. Stocks Open Higher, Trade Mixed; Piper Jaffray, Abbott Labs Rise

    IBD
  50. UPDATE: Abbott Posts Upbeat Q3 Profit, Lifts Dividend

    Benzinga
Trading Center